STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
Read full article →Tracking Medicare news, policy, and coverage changes.
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
Read full article →Recent cuts, especially to state and local health departments, are slowing and muddling the response to what's already a record year of outbreaks for diarrhea-causing cyclospora.
Read full article →The 26th International AIDS conference convenes this week. U.S. funding for HIV/AIDS work is being delayed or cut altogether, but there are also promising treatments on the horizon.
Read full article →The fresh funding will back two additional acquisitions, which executives say will be announced in the coming months.
Read full article →Virtual care and health navigation company Included Health inked a deal to acquire Firefly Health to scale health plan alternatives for employers.
Read full article →The funding will be used to advance the company’s technology and capabilities, CEO and founder Eric Leuthardt, M.D., told Fierce.
Read full article →LifeBridge Health's Sinai Hospital of Baltimore is putting an artificial intelligence-powered diagnostic for sepsis into clinical use, bringing a research-backed tool to the patients' bedside.
Read full article →Centene reported $1.1 billion in profit for the second quarter of 2026, rebounding from a loss a year ago.
Read full article →Medicaid eligibility will soon hinge on how the government defines “medical frailty.”
Read full article →President Trump responded to recently released entries from Dr. Anthony Fauci on Tuesday, saying he grew tired of the former White House medical adviser. "He was a much bigger player in the Biden administration. I grew tired of him,” Trump said in an interview with "Fox & Friends." “He wanted to close everything down. I...
Read full article →Johnson & Johnson reached a potential $5.5 billion settlement on Monday in an effort to settle past legal woes over claims that its talc products were behind cases of ovarian cancer. The settlement would cover roughly 76,000 claims with no cap on payouts. Johnson & Johnson said it plans to issue the first round of...
Read full article →Heavy TV viewers had smaller brain volumes and white matter damage tied to cognitive decline.
Read full article →